culture rather than one in which “safety first” was the
predominant value.
Reflecting on his MBA days he recalled the cost – benefit
analysis of the Ford Pinto dilemma, the Thalidomide issue
with Distillers and more recently the Martin Shkreli issues
over Daraprim and Thiola.